|Have Questions?||Leave a Message or Start an on-line Chat|
The production of the RARA recombinant monoclonal antibody involves the utilization of DNA recombinant technology and in vitro genetic manipulation. Initially, an animal is immunized with a synthesized peptide derived from human RARA, enabling the isolation of B cells. The subsequent step involves screening and selecting positive B cells, followed by the identification of a single clone. PCR amplification of the light and heavy chains of the RARA antibody is carried out, and the resulting genes are inserted into a plasmid vector. This recombinant vector is then introduced into a host cell line to facilitate the expression of the antibody. The RARA recombinant monoclonal antibody is purified from the cell culture supernatant using affinity chromatography. This antibody exhibits a specific binding affinity for human RARA protein and can be effectively employed in ELISA and IHC applications.
The RARA protein binds to RA, which causes a conformational change of RARA, causing the dissociation of the corepressor complex and the recruitment of a coactivator complex, leading to the activation of transcription of target genes. RARA is involved in various biological processes, including embryonic development, differentiation, and homeostasis in adult tissues. It plays a critical role in the development of several tissues, including the central nervous system, the heart, and the hematopoietic system. RARA also participates in the pathogenesis of certain cancers, including acute promyelocytic leukemia (APL), where it is fused to a partner protein resulting in aberrant activation of its transcriptional activity.
There are currently no reviews for this product.